Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV

@article{Pollack2002DevelopmentAU,
  title={Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV},
  author={Paul F. Pollack and Jessie R. Groothuis and Gina M Barbarotto},
  journal={Journal of Infection and Chemotherapy},
  year={2002},
  volume={8},
  pages={201-206}
}
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by respiratory syncytial virus (RSV). RSV causes significant morbidity and mortality in young children worldwide and is particularly severe in pre-term infants, children with cardiopulmonary disease, and the immunosuppressed population. The first such genetically engineered agent to be used effectively against a human infectious disease, palivizumab significantly reduces the… Expand
Targeting RSV with vaccines and small molecule drugs.
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a numberExpand
The Prophylaxis and Treatment with Antiviral Agents of Respiratory Syncytial Virus Infections
TLDR
In this review, recent advances in the discovery and development of antiviral agents for respiratory syncytial virus (RSV) infections are considered. Expand
RSV: perspectives to strengthen the need for protection in all infants
TLDR
A renaissance in RSV prevention strategies is unfolding, with several new prophylactic options such as monoclonal antibodies and maternal vaccinations that are soon to be available, and a multi-stakeholder approach is necessary to bridge data gaps to fully utilise upcoming options. Expand
Infection by the respiratory syncytial virus in infants and young children at high risk
TLDR
National and international guidelines now recommend routine prophylaxis in the first year of life in children with haemodynamically significant congenital cardiac disease, following a recent international, randomised, double-blind, placebo-controlled trial. Expand
Cytokine Elevation in Sudden Death With Respiratory Syncytial Virus: A Case Report of 2 Children
TLDR
2 RSV-related deaths of children who were born at full-term and developed normally up to the age of 19 months are presented and blood tests revealed that the IL-6 level was elevated more than >200-fold above normal, despite a normal C-reactive protein level. Expand
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
TLDR
Bamlanivimab has shown some efficacy in patients with mild to moderate COVID-19, but due to poor efficacy it is currently only usable in combination with etesevimab. Expand
Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
TLDR
The data support the importance of RSV G during infection to RSV disease pathogenesis and suggest that use of appropriately designed G peptide vaccines to reduce the risk of enhanced disease with non-live RSV vaccines merits further study. Expand
Local cytokine response upon respiratory syncytial virus infection.
TLDR
Recent research leading to the identification of RSV virulence factors that are responsible of promoting a pro-inflammatory environment at the airways and their implications on pathogenicity are discussed. Expand
Avaliação da susceptibilidade de mutantes de escape do vírus sincicial respiratório frente ao Palivizumab pelo método de microneutralização in vitro.
TLDR
This study characterized phenotypically by in vitro microneutralization assays, strains from children with no treatment with Palivizumab circulating in 2013 showing mutations in HRSV F protein, more specifically related to potential resistance in the binding epitopes of PalivIZumab, concluding that the mutations found did not confer resistance to the monoclonal. Expand
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
  • Sua Lee, Shina Jang, +16 authors Dong-Sik Kim
  • Medicine
  • Frontiers in Immunology
  • 2021
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. AntibodyExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 21 REFERENCES
Respiratory syncytial virus prophylaxis--the story so far.
TLDR
Clinical trial and outcomes data documenting experience with palivizumab to date continue to extend the initial safety and efficacy observations. Expand
Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes
TLDR
It is demonstrated that prophylaxis with palivizumab during the RSV season was associated with a low rate of hospitalization for RSV-positive lower respiratory tract infections (LRTIs) and the results confirm the results of the major randomized clinical trial of palivIZumab and demonstrate the safety and effectiveness of RSV prophYLaxis. Expand
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.
TLDR
Only 2.3% of children receiving palivizumab prophylaxis were hospitalized with RSV lower respiratory infection, which compares favorably with the rates observed in the pivotal trial (IMpact-RSV trial in 1996 to 1997), in which prophelaxis reduced hospitalization from 10.6% in the placebo group to 4.8% in those children receiving prophYLaxis. Expand
Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)
  • J. Groothuis, H. Nishida
  • Medicine
  • Pediatrics international : official journal of the Japan Pediatric Society
  • 2002
TLDR
Palivizumab offers the only option for prophylaxis against RSV disease in high‐risk infants in light of the lack of effective vaccines for this serious health risk. Expand
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
TLDR
RSV-IGIV should not be used for prophylaxis of RSV disease in children with cyanotic CHD, but it was effective in preventing RSV hospitalization in infants younger than 6 months of age. Expand
Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis
OBJECTIVE To determine the safety and efficacy of monthly prophylaxis with respiratory syncytial virus immune globulin, intravenous (RSV-IGIV) for reduction of the incidence of RSV-associatedExpand
Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.
TLDR
RSV bronchiolitis in infancy severe enough to cause hospitalization was highly associatied with the development of asthma and allergic sensitization up to age 7(1)/ (2). Expand
Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children
TLDR
Immune globulin with a high titer of antibodies against respiratory syncytial virus may offer infants and young children at risk protection from this serious, common respiratory illness. Expand
Respiratory syncytial virus infection in lower respiratory tract and asthma attack in hospitalized children in North Hokkaido, Japan
TLDR
RSV LRTI in North Hokkaido was not rare in summer, indicating that RSV was transmitted commonly among children throughout the year, and the epidemic peak was observed in November and December. Expand
Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
TLDR
Overall, RSV-Ig was more cost-effective than palivizumab for infants requiring respiratory support at 36 weeks of postconceptual age (PCA) or older, especially those born at 26 weeks' gestation or earlier. Expand
...
1
2
3
...